LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Ovarian Cancer Test Cuts Surgical Procedure Time and Infection Risk

By LabMedica International staff writers
Posted on 12 May 2022
Print article
Image: OvaCis rapid test is slated to launch in EU and Southeast Asia by 2022 end (Photo courtesy of INEX Innovate)
Image: OvaCis rapid test is slated to launch in EU and Southeast Asia by 2022 end (Photo courtesy of INEX Innovate)

The current standard of practice for ovarian cancer screening, called frozen section, increases the surgical procedure time by up to 60 minutes, consequently increasing the risk of infections and anesthesia. Frozen section is also dependent on the skill of the pathologist conducting the biopsy sections, thus ovarian cancers (especially early ovarian cancers) can be missed. Now, a first of its kind point-of-care (POCT) test discriminates benign from malignant ovarian cysts in an operating theater setting and significantly reduces surgical procedure time by providing results in 15 minutes.

The OvaCis Rapid Test from INEX Innovate (Singapore) works by identifying a protein biomarker (haptoglobin) evenly distributed in ovarian cysts fluid to determine if the cysts are benign or malignant. The reagents in the device combine to yield a colorimetric reaction which displays if the cancer is malignant (positive) or benign (negative). The test was developed as a rapid test format, and has proved to be user friendly requiring only minimal training and five minutes of hands-on time.

OvaCis’ reliance on cyst fluid which is homogenous results in higher accuracy. OvaCis is ideal for medical settings with no on-site facilities for histology, and costs less than frozen section. It does not require trained pathologists, substantially reduces operating theatre time, and frees up resources in the laboratory. OvaCis Rapid Test has obtained a CE mark and is slated to launch in the EU and Southeast Asian markets by the end of 2022. A previous iteration of OvaCis was launched in 2019, and the latest improvements now mean an extension of the product's shelf life to a minimum of 18 months at room temperature storage. This makes it convenient to store the kits in a primary healthcare setting.

“Ovarian cysts are a very common women's health condition. In fact, as many as 18% of women have them at some point in their lives and about 8% of premenopausal women develop large cysts that need treatment,” said Kane Black, Chief Executive of INEX Innovate. “With limited diagnostic options, this is an underserved population. This is mainly because the industry has been largely focused on upstream screening procedures such as early cancer detection.”

“OvaCis empowers surgeons to make fast informed evidence-based decisions within the confines of a high pressure surgical environment. By providing results in 15 minutes, the surgical procedure time is significantly reduced, thus greatly reducing the risk of infection. It also adds a layer of assurance for clinicians to make decisions about the extent of the surgery and the final reproductive status of a patient,” added Black.

Related Links:
INEX Innovate 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more